Peptide
Semaglutide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
The drugs
One page per drug. Effect sizes, trial designs, and the populations they were measured in.
Dual agonist
Tirzepatide
SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.
Oral
Oral GLP-1
Oral semaglutide and orforglipron — the same mechanism without the injection.
Related reading
Fasting Evidence
Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.
Metabolism Review
Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.
Weight Loss Evidence
Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.
Sleep Evidence
Sleep, circadian rhythm and the wearables that claim to measure both.